Literature DB >> 10644368

Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

M Moulard1, H Lortat-Jacob, I Mondor, G Roca, R Wyatt, J Sodroski, L Zhao, W Olson, P D Kwong, Q J Sattentau.   

Abstract

It is well established that the gp120 V3 loop of T-cell-line-adapted human immunodeficiency virus type 1 (HIV-1) binds both cell-associated and soluble polyanions. Virus infectivity is increased by interactions between HIV-1 and heparan sulfate proteoglycans on some cell types, and soluble polyanions such as heparin and dextran sulfate neutralize HIV-1 in vitro. However, the analysis of gp120-polyanion interactions has been limited to T-cell-line-adapted, CXCR4-using virus and virus-derived gp120, and the polyanion binding ability of gp120 regions other than the V3 loop has not been addressed. Here we demonstrate by monoclonal-antibody inhibition, labeled heparin binding, and surface plasmon resonance studies that a second site, most probably corresponding to the newly defined, highly conserved coreceptor binding region on gp120, forms part of the polyanion binding surface. Consistent with the binding of polyanions to the coreceptor binding surface, dextran sulfate interfered with the gp120-CXCR4 association while having no detectable effect on the gp120-CD4 interaction. The interaction between polyanions and X4 or R5X4 gp120 was readily detectable, whereas weak or undetectable binding was observed with R5 gp120. Analysis of mutated forms of X4 gp120 demonstrated that the V3 loop is the major determinant for polyanion binding whereas other regions, including the V1/V2 loop structure and the NH(2) and COOH termini, exert a more subtle influence. A molecular model of the electrostatic potential of the conserved coreceptor binding region confirmed that it is basic but that the overall charge on this surface is dominated by the V3 loop. These results demonstrate a selective interaction of gp120 with polyanions and suggest that the conserved coreceptor binding surface may present a novel and conserved target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644368      PMCID: PMC111673          DOI: 10.1128/jvi.74.4.1948-1960.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  88 in total

1.  A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.

Authors:  J P Moore; A Trkola; B Korber; L J Boots; J A Kessler; F E McCutchan; J Mascola; D D Ho; J Robinson; A J Conley
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

2.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  A heterologous heparin-binding domain can promote functional attachment of a pseudorabies virus gC mutant to cell surfaces.

Authors:  S J Flynn; P Ryan
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding.

Authors:  H A Harrop; D R Coombe; C C Rider
Journal:  AIDS       Date:  1994-02       Impact factor: 4.177

5.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

6.  Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D.

Authors:  A J Conley; M K Gorny; J A Kessler; L J Boots; M Ossorio-Castro; S Koenig; D W Lineberger; E A Emini; C Williams; S Zolla-Pazner
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

7.  Local and global structural properties of the HIV-MN V3 loop.

Authors:  P Catasti; J D Fontenot; E M Bradbury; G Gupta
Journal:  J Biol Chem       Date:  1995-02-03       Impact factor: 5.157

8.  Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro.

Authors:  C C Rider; D R Coombe; H A Harrop; E F Hounsell; C Bauer; J Feeney; B Mulloy; N Mahmood; A Hay; C R Parish
Journal:  Biochemistry       Date:  1994-06-07       Impact factor: 3.162

9.  A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.

Authors:  S V Warrier; A Pinter; W J Honnen; M Girard; E Muchmore; S A Tilley
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

10.  Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.

Authors:  G Roderiquez; T Oravecz; M Yanagishita; D C Bou-Habib; H Mostowski; M A Norcross
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  110 in total

1.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 2.  Receptors and entry cofactors for retroviruses include single and multiple transmembrane-spanning proteins as well as newly described glycophosphatidylinositol-anchored and secreted proteins.

Authors:  J Overbaugh; A D Miller; M V Eiden
Journal:  Microbiol Mol Biol Rev       Date:  2001-09       Impact factor: 11.056

3.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

4.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  The tailless icosahedral membrane virus PRD1 localizes the proteins involved in genome packaging and injection at a unique vertex.

Authors:  Brent Gowen; Jaana K H Bamford; Dennis H Bamford; Stephen D Fuller
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

6.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

Review 7.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Adaptation of alphaviruses to heparan sulfate: interaction of Sindbis and Semliki forest viruses with liposomes containing lipid-conjugated heparin.

Authors:  Jolanda M Smit; Barry-Lee Waarts; Koji Kimata; William B Klimstra; Robert Bittman; Jan Wilschut
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.